Skip to main content
  • Register
  • Help
  • Contact us
  • Log out of your HL account

Exelixis Inc (EXEL) Com Stk Usd0.001

Sell:$16.74 Buy:$16.75 Change: $0.37 (2.26%)
NASDAQ:0.12%
Prices delayed by at least 15 minutes | Switch to live prices |
Sell:$16.74
Buy:$16.75
Change: $0.37 (2.26%)
Prices delayed by at least 15 minutes | Switch to live prices |
Sell:$16.74
Buy:$16.75
Change: $0.37 (2.26%)
Prices delayed by at least 15 minutes | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Exelixis, Inc. is a biopharmaceutical company. The Company is focused on discovery, development and commercialization of new medicines to manage care and outcomes for people with cancer. The Company's cabozantinib product is an inhibitor of multiple tyrosine kinases, including MET, AXL, and VEGF receptors. The Company's CABOMETYX tablets are approved for previously treated advanced kidney cancer and COMETRIQ capsules are approved for progressive, metastatic medullary thyroid cancer. The third product, Cotellic, is a formulation of cobimetinib, a selective inhibitor of MEK is approved as part of a combination regimen to treat advanced melanoma. Both cabozantinib and cobimetinib have shown potential in a range of forms of cancer and are the subjects of broad clinical development programs. The Company's XL888 is a small molecule oral inhibitor of Heat Shock Protein 90 (HSP90), a molecular chaperone protein.

Contact details

Address:
1851 Harbor Bay Pkwy
ALAMEDA
94502-3016
United States
Telephone:
+1 (650) 8377000
Website:
www.exelixis.com

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
EXEL
ISIN:
US30161Q1040
Market cap:
$4.66 billion
Shares in issue:
303.85 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
NASDAQ Comb. Composite

Key personnel

  • Stelios Papadopoulos
    Independent Chairman of the Board, Co-Founder
  • Michael Morrissey
    President, Chief Executive Officer, Director
  • Christopher Senner
    Chief Financial Officer, Executive Vice President
  • Gisela Schwab
    President - Product Development and Medical Affairs, Chief Medical Officer
  • Peter Lamb
    Executive Vice President - Scientific Strategy, Chief Scientific Officer
  • Jeffrey Hessekiel
    Executive Vice President, General Counsel, Secretary
  • Patrick Haley
    Senior Vice President - Commercial

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.